ARYA Atherosclerosis Journal

Enterococcal Endocarditis: Prospective Data from the Iranian Registry of Infective Endocarditis

Document Type : Original Article(s)

Authors

Pardis Moradnejad 1
majid maleki 2
Sara Lotfian 1
Anita Sadeghpour 2
Ata Firouzi 3
Hamidreza Pasha 1
Behshid Ghadrdoost 1
shabnam boudagh 2

1 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

2 Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

3 Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

https://doi.org/10.48305/arya.2022.16325.2733
Abstract
BACKGROUND: Enterococci are responsible for 5% to 18% of infective endocarditis (IE) cases. We aimed to determine demographic data, predisposing factors, clinical presentations, complications and echocardiographic findings concerning enterococcal endocarditis.
METHODS: Since 2006, all adult patients with a possible or definite diagnosis of IE based on the modified Duke criteria have been enrolled in the Iranian Registry of Infective Endocarditis. In this study, patients with IE of enterococcal origin were detected and their demographic characteristics, predisposing factors, complications, laboratory data and echocardiographic findings were assessed.
RESULTS: Out of 731 patients diagnosed with endocarditis. Enterococci were found in 60 patients: 32 men (53.3%) and 28 women (46.7%) at a mean age of 55.21 ± 17.9 years. Definite IE was diagnosed in 57 (95%) patients, and possible IE was suspected in 3 patients (5%). The most frequent predisposing factor was the prosthetic valve (n=28, 46.7%), followed by a history of previous endocarditis (n=12, 20%). An acute course (<6 wk) was reported in 38 patients (63.3%). Fever (n=58, 95%) and loss of appetite (n=17, 28.3%) were the most frequent symptoms. The most frequent location of involvement was the aortic valve (n=22, 36.7%), followed by the mitral valve (n=20,33.3%). Vegetation was detected in 53 patients (88.3%), abscess formation in 8 (13%). Fifteen patients (25%) had heart failure, and 11 (18%) had central nervous
system complications. The mortality rate was 20%.
CONCLUSION: Given the serious complications and the high mortality rate in the patients with IE of enterococcal origin, which may be due to these organisms’ intrinsic resistance to many antibiotics, we suggest further studies to determine more effective antibiotic regimens and even individualized antibiotic therapies for enterococcal endocarditis.

Keywords

Endocarditis
Enterococcus
Staphylococcus aureus
  1. Acibuca A, Yilmaz M, Okar S, Kursun E, Acilar O, Tekin A, et al. An epidemiological study to define the recent clinical characteristics and outcomes of infective endocarditis in southern Turkey. Cardiovascular Journal of Africa. 2021;32(4):188-92.
  2. Kaçmaz AB, Balkan İİ, Sinan ÜY, Mete B, Saltoğlu N, Tabak F, et al. Epidemiological, Clinical, and Prognostic Features of Infective Endocarditis: A Retrospective Study with 90 Episodes. Cerrahpaşa Medical Journal. 2021;45(2):107-15.
  3. Wenlock R, Thornton E, Curtis S, Lewis M, Holland L, James R. 11 A 5 year study of infective endocarditis managed by a multidisciplinary team in a regional cardiothoracic centre: trends in referral, infective organisms and outcomes. BMJ Publishing Group Ltd and British Cardiovascular Society; 2021.
  4. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases E-Book: Elsevier Health Sciences; 2019.
  5. Olmos C, Vilacosta I, Fernández-Pérez C, Bernal JL, Ferrera C, García-Arribas D, et al. The evolving nature of infective endocarditis in Spain: a population-based study (2003 to 2014). Journal of the American College of Cardiology. 2017;70(22):2795-804.
  6. Selton-Suty C, Célard M, Le Moing V, DocoLecompte T, Chirouze C, Iung B, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clinical infectious diseases. 2012;54(9):1230-9.
  7. Anderson D, Murdoch D, Sexton D, Reller L, Stout J, Cabell C, et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study. Infection. 2004;32(2):72-7.
  8. Dahl A, Iversen K, Tonder N, Hoest N, Arpi M, Dalsgaard M, et al. Prevalence of infective endocarditis in Enterococcus faecalis bacteremia. Journal of the American College of Cardiology. 2019;74(2):193-201.
  9. Pericás J, Zboromyrska Y, Cervera C, Castañeda X, Almela M, Garcia-De-La-Maria C, et al. Enterococcal endocarditis revisited. Future microbiology. 2015;10(7):1215-40.
  10. Dahl A, Bruun NE. Enterococcus faecalis infective endocarditis: focus on clinical aspects. Expert review of cardiovascular therapy. 2013;11(9):1247-57.
  11. Microbiology EbtESoC, Diseases I, Infection btISoCf, Cancer, Habib G, Hoen B, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009) The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). European heart journal. 2009;30(19):2369-413.
  12. Chirouze C, Athan E, Alla F, Chu VH, Corey GR, Selton-Suty C, et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on EndocarditisProspective Cohort Study. Clinical microbiology and infection. 2013;19(12):1140-7.
  13. Fernandez‐Guerrero M, Herrero L, Bellver M, Gadea I, Roblas R, De Górgolas M. Nosocomial enterococcal endocarditis: a serious hazard for hospitalized patients with enterococcal bacteraemia. Journal of internal medicine. 2002;252(6):510-5.
  14. Moellering Jr RC, Watson BK, Kunz LJ. Endocarditis due to group D streptococci: comparison of disease caused by Streptococcus bovis with that produced by the enterococci. The American journal of medicine. 1974;57(2):239-50.
  15. Olaison L, Endocarditis KSftSSoIDQASGf. Enterococcal endocarditis in Sweden, 1995–1999: can shorter therapy with aminoglycosides be used? Clinical infectious diseases. 2002;34(2):159-66.
  16. Sadeghpour A, Maleki M, Movassaghi M, Rezvani L, Noohi F, Boudagh Sh, Ghadrdoost B, Bakhshandeh H, Alizadehasl A, Naderi N, Kamali M, A. Ghavidel AR, Peighambari MM, Kyavar M, Pasha HR. Iranian Registry of Infective Endocarditis (IRIE): Time to relook at the guideline, regarding to regional differences. IJC Heart & Vasculature 26 (2020) 100433.
  17. Sadeghpour A, Maleki M, Boodagh Sh, Behjati B, Rezvani L, Ghadrdoost B, Noohi F, Bakhshandeh H, Moradnejad P, Kamali M, Alizadehasl A, Ghavidel A, Hosseini S, Pasha H. Impact of the Iranian Registry of Infective Endocarditis (IRIE) and multidisciplinary team approach on patient management, Acta Cardiologica, 2020; DOI: 10.1080/00015385.2020.1781423
  18. Moradnejad P, Esmaeili S, Maleki M, Sadeghpour A, Kamali M, Rohani M, Ghasemi A, Bagheri Amiri F, Pasha HR, Boudagh SH, Bakhshandeh H, Naderi N, Ghadrdoost B, Lotfian S, Dehghan Manshadi SA, Mostafavi E. Q Fever Endocarditis in Iran. Scientific Reports. (2019) 9:15276 | https://doi.org/10.1038/ s41598-019-51600-3.
  19. Pericàs JM, Llopis J, Muñoz P, Gálvez-Acebal J, Kestler M, Valerio M, et al. A contemporary picture of enterococcal endocarditis. Journal of the American College of Cardiology. 2020;75(5):482-94.
  20. Bouza E, Kestler M, Beca T, Mariscal G, RodríguezCréixems M, Bermejo J, et al. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. Clinical Infectious Diseases. 2015;60(4):528-35.
  21. Dahl A, Lauridsen TK, Arpi M, Sørensen LL, Østergaard C, Sogaard P, et al. Risk factors of endocarditis in patients with Enterococcus faecalis bacteremia: external validation of the NOVA score. Clinical Infectious Diseases. 2016;63(6):771-5.
  22. Guerrero MLF, Goyenechea A, Verdejo C, Roblas RF, de Górgolas M. Enterococcal endocarditis on native and prosthetic valves: a review of clinical and prognostic factors with emphasis on hospital-acquired infections as a major determinant of outcome. Medicine. 2007;86(6):363-77.
  23. McDonald J, Olaison L, Anderson D, Hoen B, Miro J, Eykyn S, et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. The American journal of medicine. 2005;118(7):759-66.
  24. Murray BE. The life and times of the Enterococcus. Clinical microbiology reviews. 1990;3(1):46-65.
  25. Munita JM, Arias CA, Murray BE. Enterococcal endocarditis: can we win the war? Current infectious disease reports. 2012;14(4):339-49.
  26. Rice LB, Calderwood SB, Eliopoulos GM, Farber BF, Karchmer AW. Enterococcal endocarditis: a comparison of prosthetic and native valve disease. Reviews of infectious diseases. 1991;13(1):1-7.
  27. Baddour LM, Wilson WR, Bayer AS, Fowler Jr VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435-86.
  28. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC) endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). European heart journal. 2015;36(44):3075-128.
ARYA Atherosclerosis Journal
Volume 18, Issue 5
May 2022
Pages 1-8

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us